HDAC9 and neoplasm: Specifically, taxane and platinum‐based chemotherapeutics stimulate tumor‐specific CD8 T cell responses,40, 41 which class I HDAC inhibition might elaborate by improving tumor‐specific T cell function and impairing intratumoral suppressive networks.